Maze Therapeutics (MAZE) CSBO Atul Dandekar Exercises RSUs

What Happened

• Atul Dandekar, Chief Strategy & Business Officer of Maze Therapeutics, had a derivative transaction reported on 2026-09-01: 12,500 shares were acquired via exercise/conversion of a derivative (reported as $0.00) and the filing also shows 12,500 shares disposed (also $0.00). The report lists zero cash value for both entries.
• This transaction reflects conversion/settlement of restricted stock units (RSUs), not an open-market purchase or a standard cash sale. It is generally a vesting/settlement event rather than a market-direction trade.

Key Details

• Transaction date: 2026-09-01; Price reported: $0.00 for both acquired and disposed entries.
• Shares: 12,500 acquired (exercise/conversion), 12,500 disposed (derivative) on same date.
• Shares owned after the transaction: not disclosed in the provided filing details.
• Footnotes of note:
  • F1: Each RSU represents a contingent right to one share upon settlement.
  • F2: The award vests 1/2 on Sept 1, 2026 and 1/2 on Sept 1, 2027, subject to continued service.
  • F3: These RSUs do not expire; they either vest or are cancelled prior to vesting.
• Filing timeliness: Report filed 2026-09-03 for a 2026-09-01 transaction; no late filing indicator reported.

Context

• This was a derivative/RSU settlement event (code M on the form) rather than a straightforward buy or sale in the open market. The equal acquired and disposed amounts and $0.00 prices indicate a settlement/transfer-type action; the filing does not specify the reason for the disposition (e.g., sale, tax withholding, or cancellation).
• For retail investors: conversions/vestings are routine compensation events and do not by themselves imply insider bullishness or bearishness on the stock price.